TG Therapeutics (TGTX) Q4 2025 Earnings Transcript [Yahoo! Finance]
TG Therapeutics, Inc. (TGTX)
Last tg therapeutics, inc. earnings: 11/12 07:34 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.tgtherapeutics.com
Company Research
Source: Yahoo! Finance
Image source: The Motley Fool. Date Thursday, Feb. 26, 2026 at 8:30 a.m. ET Call participants Chairman and Chief Executive Officer — Michael S. Weiss Chief Commercial Officer — Adam Waldman Chief Financial Officer — Sean Power Need a quote from a Motley Fool analyst? Email pr@fool.com Full Conference Call Transcript Michael Weiss: Thank you, Jenna, and good morning, everyone, and thank you for joining us today. 2025 was a defining year for TG Therapeutics. We didn't just grow, we scaled, we strengthened and we demonstrated that BRIUMVI is becoming a foundational therapy in relapsing multiple sclerosis. Let's start with what matters most, performance. We delivered approximately $616 million in total global revenue, the vast majority of which came from $594 million of BRIUMVI U.S. net sales, and we capped the year with a strong fourth quarter of $183 million. That represents approximately 92% year-over-year growth and 20% sequential growth from Q4 over Q3. Those numbe
Show less
Read more
Impact Snapshot
Event Time:
TGTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TGTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TGTX alerts
High impacting TG Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
TGTX
News
- TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the American Academy of Neurology 2026 Annual MeetingGlobeNewswire
- TG Therapeutics: Flawless Execution And $500 Million Non-Dilutive Capital Bolster Outlook [Seeking Alpha]Seeking Alpha
- A Look At TG Therapeutics (TGTX) Valuation After Recent Share Price Momentum [Yahoo! Finance]Yahoo! Finance
- TG Therapeutics concludes enrolment in Phase III Briumvi trial [Yahoo! Finance]Yahoo! Finance
- TG Therapeutics Announces Completion of Enrollment for the Phase 3 Trial Evaluating Subcutaneous BRIUMVI [Yahoo! Finance]Yahoo! Finance
TGTX
Earnings
- 2/26/26 - Miss
TGTX
Analyst Actions
- 2/2/26 - JP Morgan
TGTX
Sec Filings
- 3/27/26 - Form SCHEDULE
- 3/20/26 - Form 8-K
- 2/27/26 - Form 10-K
- TGTX's page on the SEC website